News
Emerging data help inform immunotherapy for urothelial cancer
Atezolizumab had a marked survival benefit vs. chemotherapy in patients with TMB-high, PD-L1–positive urothelial tumors.
News
New treatment options emerge for intermediate, advanced HCC
SAN FRANCISCO – Two new therapies that target VEGF signaling are efficacious and may expand the treatment for intermediate and advanced HCC.
News
Enzalutamide shines in nonmetastatic castration-resistant prostate cancer
SAN FRANCISCO - Metastasis-free survival was 36.6 months with enzalutamide and 14.7 months with placebo.
News
Bladder cancer: Two chemoradiation therapy regimens on par for muscle-invasive disease
Primary results were comparable in the NRG/RTOG 0712 trial, but one regimen is more convenient.
News
Adjuvant chemo halves DFS events in upper-tract urothelial cancer
SAN FRANCISCO - Trial enrollment was stopped early, after a median follow-up of 19.3 months, because of efficacy of chemotherapy.
News
Adding docetaxel to hormone therapy for advanced prostate cancer nets QOL benefit
SAN FRANCISCO – Adding docetaxel to first-line long-term hormone therapy for advanced prostate cancer, whether metastatic or not, improves quality...
News
Pembrolizumab nets durable responses in sorafenib-treated advanced HCC
With a median follow-up of 8.4 months, the overall response rate was 16.3% and the median duration of response was 8.2 months.
News
Atezolizumab-bevacizumab combo tops sunitinib as first-line therapy for RCC
With a median follow-up of 15 months, compared with sunitinib, the combination of atezolizumab and bevacizumab prolonged investigator-assessed...
News
New model predicts survival in atezolizumab-treated advanced urothelial carcinoma
The model contains six factors and predicts survival of patients given the immune checkpoint inhibitor atezolizumab in the postplatinum setting....
News
Sequence of regorafenib, cetuximab matters in later-line CRC therapy
SAN FRANCISCO – Median overall survival was 17.4 months when regorafenib was given first and 11.6 months when cetuximab was given first in later-...
News
ROBOT trial compares surgical approaches to esophagectomy
The robot-assisted method works for patients with resectable esophageal cancer.
News
Apalutamide wins big in SPARTAN prostate cancer trial
The androgen-receptor antagonist is highly effective for treating nonmetastatic castration-resistant prostate cancer.
News
First-line ramucirumab nets small PFS benefit in gastric cancer
Median progression-free survival was 5.85 months with ramucirumab and 5.55 months with placebo.
News
Combination immunotherapy is active in dMMR/MSI-H metastatic colorectal cancer
With median follow-up of 13.4 months, 55% of metastatic CRC patients had a response to the combination of nivolumab and ipilimumab in the...
News
Circulating tumor cell assay shows promise for colorectal cancer screening
The CTC assay had an accuracy of 87.9% in the entire cohort of 620 colonoscopy patients, which included 327 patients with colorectal cancer of all...
